SuperworthNeogen free cash flow NEOG
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Aug 31, 2026
- $49.7M
- Latest quarter, Q1 FY27
- $4.7M
- Fiscal year 2026
- $31.8M
Neogen's free cash flow was $49.7M over the twelve months to Aug 31, 2026.
In its latest quarter, Q1 FY27, it was $4.7M.
Over the five fiscal years to FY2026 it shrank 10% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2026 | $31.8M | n/a |
| FY2025 | −$46.4M | n/a |
| FY2024 | −$76.2M | n/a |
| FY2023 | −$24.7M | −157% |
| FY2022 | $43.6M | −20% |
| FY2021 | $54.4M | −12% |
| FY2020 | $61.8M | +26% |
| FY2019 | $49.2M | +2% |
| FY2018 | $48.2M | +5% |
| FY2017 | $45.7M | +116% |
| FY2016 | $21.1M | −38% |
| FY2015 | $34.2M | +238% |
| FY2014 | $10.1M | −43% |
| FY2013 | $17.7M | +79% |
| FY2012 | $9.9M | −53% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $4.7M | n/a | $49.7M | |
| Q4 FY26 | $26.2M | +8406% | $31.8M | |
| Q3 FY26 | $11.1M | n/a | $6M | |
| Q2 FY26 | $7.8M | −66% | −$18.5M | |
| Q1 FY26 | −$13.2M | n/a | −$3.2M | |
| Q4 FY25 | $308K | −88% | −$46.4M | |
| Q3 FY25 | −$13.4M | n/a | −$44.2M | |
| Q2 FY25 | $23.1M | n/a | −$93.1M | |
| Q1 FY25 | −$56.3M | n/a | −$124.9M | |
| Q4 FY24 | $2.5M | −96% | −$76.2M | |
| Q3 FY24 | −$62.3M | n/a | −$13.2M | |
| Q2 FY24 | −$8.7M | n/a | $16.9M |
Against its peers
Companies in Medical - Diagnostics & Research nearest Neogen's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| NEOGNeogen | 1.9% |
| CDNACareDx | n/m |
| VCYTVeracyte | 4.3% |
| BLLNBillionToOne | 0.7% |
| LNTHLantheus | 6.0% |
| CAICaris Life Sciences | 1.4% |
| BIOBio-Rad Laboratories | 3.6% |
| NRCNRC Health | 4.5% |
| RVTYRevvity | 3.2% |
| MEDPMedpace | 3.8% |
| Peer median | 3.7% |
Where Neogen ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Neogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.